[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630717":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":33,"collaborators":37,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":11,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":11},{"fullName":5,"class":6},"Goed Medisch Centrum","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Platelet-rich plasma group A","EXPERIMENTAL",null,[13],"Biological: Platelet-Rich Plasma (PRP) Injections",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group B","PLACEBO_COMPARATOR","Saline",[19],"Drug: Saline (0.9% NaCl)",[21,26],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"BIOLOGICAL","Platelet-Rich Plasma (PRP) Injections","Autologous platelet-rich plasma (PRP) is prepared from 90 mL of the participant's venous blood using a standardized two-step centrifugation protocol (ACP® Max system, Arthrex Inc.). The first centrifugation is performed at 3200 rpm for 9 minutes, followed by a second centrifugation at 1500 rpm for 5 minutes, resulting in approximately 2 mL of PRP. A single injection of 2 mL PRP is administered under sterile conditions and ultrasound guidance into the CMC-I joint, consisting of 1 mL intra-articular and 1 mL peri-articular injection. No repeated injections are performed.",[9],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Saline (0.9% NaCl)","Participants receive a placebo injection consisting of 2 mL sterile saline (0.9% NaCl), administered under sterile conditions and ultrasound guidance into the CMC-I joint. The injection protocol is identical to the PRP group, with 1 mL injected intra-articularly and 1 mL peri-articularly. To maintain blinding, participants in the placebo group undergo a venous blood draw mimicking the PRP preparation procedure; however, the collected blood is discarded. The duration and procedural steps are standardized to ensure comparable treatment conditions between groups. No repeated injections are performed.",[15],[32],"Placebo injection",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Evi Loos","Prinicpal Investigator",[38],{"name":39,"class":40},"Arthrex, Inc.","INDUSTRY","100630717","phase-2-thumb-base-osteoarthritis-ultrasound-guided-platelet-rich-plasma-versus-placebo-injection-100630717",false,"NCT07491302","Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection","Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (Thumbs-up Study)","Thumbs-up","Inclusion Criteria:\n\n* Age 18 or older\n* Patients with an Eaton-littler score of I, II or III\n* Patients with uni- or bilateral CMC-I osteoarthritis\n* Non-responders to conservative therapy i.e., hand therapy and immobilisation after 3 months\n\nExclusion Criteria:\n\n* Aged below 18\n* Patients with an Eaton-littler score of IV (STT arthrosis)\n* Surgical interventions of the CMC-I joint\n* A known articular systemic disease (e.g. rheumatoid arthritis) or additional hand osteoarthritis\u002F tenosynovitis or metabolic disease like diabetes mellitus\n* Patients with an infectious arthritis of CMC-I joint\n* A known psychiatric condition\n* Neuropathic chronic pain syndrome\n* Intra articular injection 6 months prior to inclusion\n* Smoking\n* Active use of statins","ALL","18 Years",{"count":52,"type":53},88,"ESTIMATED","INTERVENTIONAL",[56],"PHASE2","The goal of this clinical trial is to evaluate whether platelet-rich plasma (PRP) injections improve pain and function in adults with thumb base osteoarthritis (CMC-I OA).\n\nThe main questions it aims to answer are:\n\nDoes a PRP injection reduce pain compared to a placebo (saline) injection? Does PRP improve hand function, strength, and thumb mobility? What adverse events occur following PRP treatment?\n\nResearchers will compare PRP injections to a placebo injection (saline solution) to determine whether PRP is an effective treatment for CMC-I osteoarthritis.\n\nParticipants will:\n\nReceive a single ultrasound-guided injection of PRP or placebo (saline) in the CMC-I joint.\n\nAttend follow-up visits at 3, 6, 9, and 12 months for clinical assessments. Complete questionnaires on pain (VAS) and hand function (MHQ-DLV) at multiple time points.\n\nUndergo physical examinations (grip strength, pinch strength, thumb motion). Undergo ultrasound evaluations to assess joint characteristics.",[59],"Thumb Osteoarthritis",[61,62,63,64,65,66,67,68,69],"platelet-rich plasma","CMC-I joint","carpometacarpal joint osteoarthritis","Thumb base osteoarthritis","PRP injection","Placebo-controlled trial","Orthobiologics","Regenerative medicine","Ultrasound-guided injection","NOT_YET_RECRUITING","2026-04-03",{"date":73,"type":74},"2026-04-09","ACTUAL",{"date":76,"type":53},"2026-04",{"date":78,"type":53},"2027-06",{"name":5,"class":6}]